Suvannasankha, A., Kazeem, B., MacLeod, P., Dlotko, E., Boytsov, N., Samyshkin, Y., McNamara, S., Purser, M., Sapra, S., Kaiser, M. (2025). Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy. Blood. https://doi.org/10.1182/blood-2025-4041